---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-007922"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:05:01.204856+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences reports Q3 net loss of $1.1M; R&D spend up 156% on DNase platform

## Summary
- Net loss of $1.1M for Q3 2023; cash at $9.8M.
- R&D expenses rose 155.9% to $1.0M on DNase platform preclinical work.
- Royalty income from Takeda sublicense up 47.5% to $0.6M.
- Advancing DNase platform toward first-in-human study for pancreatic carcinoma.
- G&A expenses down 14.6% to $0.7M.

## SEC filing metadata
- accession: 0001683168-23-007922
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316823007922/0001683168-23-007922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316823007922/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-007922
- JSON: https://secwatch.observer/filing/0001683168-23-007922.json
- Plain text: https://secwatch.observer/filing/0001683168-23-007922.txt

## Key facts
- Earnings Releases
  Xenetic Biosciences, Inc. reported financial results for the three months ended September 30, 2023.
  - Period: the three months ended September 30, 2023
  - Result: reported results
  source text: On November 10, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316823007922/0001683168-23-007922-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.